Several acyl derivatives of hitachimycin have been synthesized and their activities, including antibacterial, cytocidal against HeLacells and in vivo antitumor against sarcoma 180, evaluated. Someof these derivatives showed higher antitumor activity than hitachimycin.
r Chemical shifts in ppmare downfield from TMS.
mycin bearing a free hydroxy group at the C-ll position. One was a selective acylation of the 15-hydroxy group and the other a selective removal of the 1 1-Oacyl group of ll,15-di-O-acylate. 1 was treated with an equivalent amount of butyric anhydride in pyridine under cooling, but the 15-butyrate was obtained in only 18.4% yield and large amount of starting material was recovered. Accordingly, the acid hydrolysis was examined. Trifluoroacetic acid (TFA) was found to be the most effective acid so far examined. The ll,15-di-O-acylates (3~5) was treated with TFAat room temperature for 5 minutes to obtain the 15-O-acylates (6~8) in quantitative yields. The 13C NMRspectra of these compounds showed signals assignable to one acyl group and the C-ll carbon signal (3 186.21 86.6) exhibited a downfield shift compared to the corresponding chemical shift of 1.
for hitachimycin derivatives. The ll,15-di-O-acylates (9~14) substituted with two different acyl groups, were synthesized by treatment of 6~8 with appropriate acid anhydrides.
In order to modify the Oi l hydroxy group selectively, it is necessary to protect the C-15 hydroxy group which is more reactive as described above. Since the acyl group at the C-ll position is labile in acidic and basic conditions, the removal of the protective group must proceed around neutrality. A trimethylsilyl (TMS) group was found to be suitable for this purpose. Treatment of 1 with trimethylsilyl chloride in pyridine afforded 15-O-trimethylsilylhitachimycin (2). 2 was reacted with an acid anhydride in pyridine to afford l l-O-acyl-15-O-trimethylsilylhitachimycins, followed by methanolysis to remove TMSgroup, giving the 1 1-Oacylates (15~17).
Chemical shift values for 13C NMRspectra of all synthesized acylates are listed in Table 1 . From comparison of the chemical shifts of the acyl groups of these compounds,it was found that there was a correlation between the bonding position of the acyl groups and the chemical shifts of the acyl carbons, as shown in Table 2 , which may be useful for determining the position of acyl groups in the other hitachimycin derivatives. A similar correlation between bonding position and chemical shifts is known in the acyl derivatives of spiramycin I9).
Cytocidal and Antibacterial Activities
Cytocidal activities against HeLa cells measured by IC50 values and MIC Og/ml) against various bacteria of hitachimycin derivatives are given in Table 3 . All compounds showed lower antibacterial activities than that of hitachimycin.
On the other hand, ll,15-di-O-acetyl (3) and l l ,1 5-di-<9-butyrylhitachimycin (5) showed high cytocidal activities. Amongthe derivatives, there
were no correlation betweenantibacterial activities and cytocidal activities. Antitumor Activity
Antitumor activities (in life span: ILS) at optimal dose of hitachimycin derivatives against sarcoma 180 are given in Table 4 . It is notable that 1 1 -O-propionyl-15-0-butyrylhitachimycin 
MICs
MICvalues against various bacteria were determined by the agar dilution method using heart infusion agar (pH 7.0).
Cytocidal Activities HeLaS3 cells were maintained in monolayers in Eagle's minimumessential mediumsupplemented with 10% bovine serum and kanamycin (100 jug/ml) at 37°C. To determine the cytocidal activities of hitachimycin derivatives, HeLa S3 cells (5 x 104) in 1.5 ml of mediumwere placed in a tissue culture plate (Falcon, 24-well) and incubated for 24 hours at 37°C in a 5% CO2 -95% air atmosphere. Each culture well was treated with 0.5 ml of fresh mediumcontaining a different concentration of hitachimycin, and reincubated for 72 hours. The cells were trypsinized to form a single cell suspension, and were counted in a hemocytometer.
Antitumor Activity Sarcoma 180 cells (1 x 106 cells/mouse) were inoculated ip into ICR mice on day 0. Mice received various doses (<250 mg/kg) of hitachimycin derivatives for 5 successive days from day 1. Antitumor activity was evaluated by the increase ILS: (T/C-l) x lOO%at the optimal dose for each derivatives, where "T" is the median survival days (MSD)of the treated group and "C" is the MSDof the control group. 1 1 , 1 5-Di-O-acetylhitachimycin (3) To a solution of 1 (91 mg) in pyridine (2.0 ml), acetic anhydride (0.2 ml) was added and set for 4 hours at room temp. The reaction mixture was diluted with CHC13 (50 ml) and washed with H2O. The CHC13 layer was dried over anhydrous sodium sulfate and evaporated under reduced pressure, to give a brown solid, which was chromatographed on a silica gel column with benzene -Me2CO 1 5-Q-Propionylhitachimycin (7) 4 (50 mg) was treated with TFA(0.5 ml) in a similar manner to the preparation of 6, to give a (1 1-OCOCH2CH3 (15) To a solution of 2 (60 mg) in pyridine (1.0 ml), acetic anhydride (0.05 ml) was added and set for 4 hours at room temp. The reaction mixture was diluted with CHC13 (50 ml) and poured into H2O. The organic layer was dried over anhydrous sodium sulfate and evaporated under reduced pressure, to give a brown solid. The brown solid was dissolved in MeOHand stirred for 12 hours. The solution was evaporated under reduced pressure, to give a brown oil, which was chromatographed on a silica gel column with CHC13 -MeOH(100 : 1), to afford as a colorless powder 15, 23 mg (41. 1 1 -O-Propionylhitachimycin (16) To a solution of 2 (60 mg) in pyridine (1.0 ml), propionic anhydride (0.05 ml) was added and set for 24 hours at room temp. The reaction mixture was treated in a similar manner to the preparation of 15, to give a colorless powder of 16, 18 mg (27.2%) with hitachimycin (16 mg) and compound 1 1 -0-Butyrylhitachimycin (17) To a solution of 2 (60 mg) in pyridine (1.0 ml), butyric anhydride (0.05 ml) was added and set for 24 hours at roomtemp. The reaction mixture was treated in a similar manner to the preparation of 15, to give colorless powder of 17, 15 mg (24.8%) with hitachimycin (13 mg) and compound 5 (7 
